Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
At the center of the collapse is opposition from the Federal Trade Commission
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
